Publications by authors named "Adel El Feky"
: Recruitment to trials can be challenging. Currently, non-randomised evaluations of trial recruitment interventions are rejected due to poor methodological quality, but systematic assessment of this substantial body of work may inform trialists' decision-making about recruitment methods. Our objective was to quantify the effects of strategies to improve participant recruitment to randomised trials evaluated using non-randomised study designs.
View Article and Find Full Text PDFArticle Synopsis
- - Data collection in clinical trials is resource-intensive, impacting trial costs and participant burden; understanding data types and proportions can optimize resource use.
- - This study categorizes data from 18 randomized trials into primary outcomes, secondary outcomes, and 15 other categories, utilizing a structured procedure for accuracy.
- - Key findings reveal primary outcomes represent only a small fraction (5.0% median) of data collected, while secondary outcomes account for a much larger portion (39.9% median), highlighting the prevalence of non-outcome data in trials.
The evidence base available to trialists to support trial process decisions-e.g. how best to recruit and retain participants, how to collect data or how to share the results with participants-is thin.
View Article and Find Full Text PDFRandomised trials are a central component of all evidence-informed health care systems and the evidence coming from them helps to support health care users, health professionals and others to make more informed decisions about treatment. The evidence available to trialists to support decisions on design, conduct and reporting of randomised trials is, however, sparse. Trial Forge is an initiative that aims to increase the evidence base for trial decision-making and in doing so, to improve trial efficiency.
View Article and Find Full Text PDFBackground: Randomised control trials are regarded as the gold standard for evaluating the effectiveness and efficacy of healthcare interventions with thousands of trials published every year. Despite significant investment in infrastructure, a staggering number of clinical trials continue to face challenges with retention. Dropouts could lead to negative consequences-from lengthy delays to missing data that can undermine the results and integrity of the trial.
View Article and Find Full Text PDF